Skip to main content

Table 1 Inputs of the decision model for the evaluation of IVIG for severe sepsis/septic shock: parameter values and uncertainty over parameter values

From: Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

Parameter

Source

Base case

Notes on scenario analyses undertaken

Notes on subgroup analyses

Cohort characteristics

    

Mean age of a severe sepsis patient at admission to hospital

CMPD

63 years old

Same as base case

Assumed to vary in subgroups defined using age. Sourced from ICNARC database

Proportion of males in a severe sepsis population at admission to hospital

CMPD

0.53

Same as base case

Assumed to vary in subgroups defined using gender. Sourced from CMPD

Short-term outcomes (ST)

    

Probability of dying in hospital when SC is used in the treatment of severe sepsis (baseline risk)

CMPD

40.6%, 95% CI (40%, 41.2%)

Same as base case

Assumed to vary per subgroup (all). Sourced from CMPD

Odds ratio, when IVIG is used to complement SC in the treatment of severe sepsis (based on Model M1)

Evidence synthesis (‘Clinical effectiveness of IVIG’)

0.75 , 95% CI (0.58, 0.96)

Alternative models tested; see Table 2

Same as base case

Longer-term outcomes (LT)

    

Age specific probability of dying in yearly intervals, conditional on patients having survived up to the start of the year.

Cuthbertson database and general population life tables 2010

Figure 4. Varies with time.

(1) time horizon

Assumed to vary for subgroups defined using age and APACHE II score. Sourced from CMPD

(2) time points at which patients reverted to survival of general population

Cost-related parameters

    

Costs of overall IVIG therapy

Non-stochastic, BNF

£5,539.05

Same as base case

Same as base case

Costs of SC, when only SC is used in the treatment of severe sepsis

Non-stochastic,

£0

Same as base case

Same as base case

LOS in ICU for patients remaining alive until discharge from hospital

CMPD

8.48 (SE = 0.086)

Same as base case

Assumed to vary for all subgroups. Sourced from CMPD

LOS in ICU for patients dying in hospital

CMPD

7.40 (SE = 0.108)

Same as base case

Assumed to vary for all subgroups. Sourced from CMPD

Costs associated to a day in ICU for a patient with severe sepsis

Non-stochastic, reference costs [24]

£1,393

Same as base case

Same as base case

Overall hospital LOS for patients remaining alive until discharge from hospital

CMPD

21.29 (SE = 0.292)

Same as base case

Assumed to vary for all subgroups. Sourced from CMPD

Overall hospital LOS for patients dying in hospital

CMPD

39.07 (SE = 0.325)

Same as base case

Assumed to vary for all subgroups. Sourced from CMPD

Costs associated to a day in wards other than ICU for a patient with a severe sepsis episode

Non-stochastic, reference costs [24]

£196

Same as base case

Same as base case

Costs incurred between year t-1 and year t after hospital discharge

Manns [25]

t = 1: £13,654 and t >1: £4,466.5/year

(1) ± 50% of Manns’ estimates

Same as base case

(2) average annual per capital NHS cost for the general population

Utilities

    

In-hospital HRQoL weight associated to severe sepsis patients

Drabinsky [26]

0.53

Same as base case

Same as base case

HRQoL weight associated to severe sepsis patients at year t

Cuthbertson database, Drabinsky [26]

t = 1: 0.62 and t >1: 0.6833

Same as base case

Same as base case

  1. See NIHR HTA full technical report [10] for a comprehensive reporting of parameter values used to inform the decision model, including those used in subgroup analyses. IVIG, intravenous immunoglobulin; CMPD, Case Mix Programme Database; ICNARC, Intensive Care National Audit & Research Centre; CI, confidence interval; BNF, British National Formulary; SC, standard care; APACHE II, Acute Physiology and Chronic Health Evaluation II; LOS, length of stay; HRQoL, health-related quality of life.